1 / 7

Europe biosimilar market size

Several blockbuster biologics are expected to lose their patent protection over the next 5-10 years. This expiration to create huge opportunities for biosimilar manufacturers. Get Biosimilar Market growth and opportunities in Europe at - https://www.aarkstore.com/healthcare/1132022/biosimilar-market-in-europe-industry-trends-share-size-growth-opportunity-and-forecast #BioSimilar #Healthcare #Mediacal #Pharmaceutical #MarketResearch #biotherapeutic

Aarkstore1
Download Presentation

Europe biosimilar market size

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aarkstore Market Research

  2. Europe Biosimilar Market Trends

  3. Summary Europe Biosimilar Market - Industry Trends, Market Size, Share and Forecast 2024 By 2024, the European Biosimilar Market size to reach 11,663.1 Million, with a CAGR of 24.9% in the forecasted period 2019-2024. This Europe Biosimilar market is to grow robustly in 2019-2024 period, as a number blockbuster biologics scheduled to lose patent protection in Europe. The Europe Biosimilar Research Report offers the supply market dynamics and forecasts future revenues for key biosimilar in the European region.

  4. Market Summary Country-wise, the market has been segmented into Italy, Germany, United Kingdom, France, Spain and Others. In 2018, Italy represented the largest market for biosimilars in Europe. The report has analyzed the market on the basis of the molecule. In 2018, Infliximab dominated the market, accounting for the highest sales. Other major molecules include Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc.

  5. Key Players • Novartis • Pfizer • Teva • Celltrion • Samsung Bioepis • Amgen • Apotex • Ratiopharm • Mylan • Merck Sharp & Dohme • Eli Lilly

  6. Related Reports • https://www.aarkstore.com/healthcare/186589/biosimilars-european-payer-perspectives • https://www.aarkstore.com/healthcare/186620/biosimilars-us-payer-perspectives • https://www.aarkstore.com/healthcare/1132022/biosimilar-market-in-europe-industry-trends-share-size-growth-opportunity-and-forecast • https://www.aarkstore.com/medical-devices/1117852/southeast-asia-biosimilars-market-report-2014-2024-market-size-share-price-trend-and-forecast • https://www.aarkstore.com/biotechnology/1136383/biosimilars-global-markets

  7. Thank You ! For More Details Please visit www.aarkstore.com +91 7710006788 | contact@aarkstore.com

More Related